HR and breast cancer: In a cohort of patients diagnosed with HR+, HER2− advanced breast cancer, characterized by either de novo metastatic disease or late recurrence following neoadjuvant therapy, the frontline combination of ribociclib and letrozole significantly prolonged the OS over letrozole alone.